Renal and Urogenital
A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, SAR442970, and rilzabrutinib in male and female participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD) (RESULT)
This is a Phase 2a, randomized, double-blind, placebo-controlled study to evaluate the efficacy, tolerability, and safety of frexalimab, SAR442970, and rilzabrutinib in participants from 16 to 75 years of age with biopsy-proven primary FSGS or MCD, with eGFR ≥ 45 mL/min/1.73 m2, and UPCR ≥ 3 g/g at screening, who have demonstrated at least partial response (≥ 40% UPCR
reduction) to at least one previous immunosuppressive therapy.
The purpose of this study is to measure the change in proteinuria and its impact ...
GO TO STUDY